Center for Scientific Review; Notice of Closed Meeting, 2555 [2019-01400]

Download as PDF Federal Register / Vol. 84, No. 26 / Thursday, February 7, 2019 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Cardiovascular and Respiratory Sciences Integrated Review Group; Respiratory Integrative Biology and Translational Research Study Section. Date: February 20–21, 2019. Time: 7:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Baltimore Marriott Waterfront, 700 Aliceanna Street, Baltimore, MD 21202. Contact Person: Bradley Nuss, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4142, MSC 7814, Bethesda, MD 20892, 301–451– 8754, nussb@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: February 1, 2019. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–01400 Filed 2–6–19; 8:45 am] BILLING CODE 4140–01–P [FR Doc. 2019–01348 Filed 2–6–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of an Exclusive Patent License: Virus-Like Particles Vaccines Against Human Polyomaviruses, BK Virus (BKV) and JC Virus (JCV) ACTION: National Institutes of Health, Notice. The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the U.S. and foreign Patents and Patent Applications listed in the Supplementary Information section of this notice to BioE Holdings Inc. (parent company, Biological E Ltd.) located in Los Altos, California. SUMMARY: National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Jkt 247001 Dated: February 1, 2019. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. HHS. National Institutes of Health 17:23 Feb 06, 2019 Name of Committee: National Cancer Institute Special Emphasis Panel; Outstanding Investigator Award (OIA). Date: March 7–8, 2019. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Boulevard, Gaithersburg, MD 20878. Contact Person: Klaus B. Piontek, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W116, Bethesda, MD 20892–9750, 240–276–5413 klaus.piontek@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) AGENCY: DEPARTMENT OF HEALTH AND HUMAN SERVICES VerDate Sep<11>2014 as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. PO 00000 Frm 00069 Fmt 4703 Sfmt 4703 2555 Only written comments and/or applications for a license which are received by the National Cancer Institute’s Technology Transfer Center on or before February 22, 2019 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Kevin W. Chang, Ph.D., Senior Technology Transfer Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, Rm. 1E530 MSC 9702, Bethesda, MD 20892–9702 (for business mail), Rockville, MD 20850– 9702, Telephone: (240)–276–5530; Facsimile: (240)–276–5504, Email: changke@mail.nih.gov. SUPPLEMENTARY INFORMATION: DATES: Intellectual Property United States Provisional Patent Application No. 61/508,897 filed July 18, 2011 and entitled, ‘‘Methods and Compositions for Inhibiting Polyomavirus-Associated Pathology’’ [HHS Reference No. E–168–2011–0–US– 01]; PCT Patent Application No. PCT/ US2012/047069 filed July 17, 2012, and entitled, ‘‘Methods and Compositions for Inhibiting Polyomavirus-Associated Pathology’’ [HHS Reference No. E–168– 2011–0–PCT–02]; Australian Patent No. 2012284122 issued September 14, 2017, and entitled, ‘‘Methods and Compositions for Inhibiting Polyomavirus-Associated Pathology’’ [HHS Reference No. E–168–2011–0– AU–03]; Canadian Patent Application No. 2842180 filed July 17, 2012 and entitled, ‘‘Methods and Compositions for Inhibiting Polyomavirus-Associated Pathology’’ [HHS Ref. No. E–168–2011– 0–CA–04]; European Patent Application No. 12741191.6 filed July 17, 2012 and entitled, ‘‘Methods and Compositions for Inhibiting Polyomavirus-Associated Pathology’’ [HHS Ref. No. E–168–2011– 0–EP–05]; Japanese Patent No. 6030650 issued October 28, 2016 and entitled, ‘‘Methods and Compositions for Inhibiting Polyomavirus-Associated Pathology’’ [HHS Ref. No. E–168–2011– 0–JP–06]; United States Patent No. 9,764,022 issued September 19, 2017 and entitled, ‘‘Methods and Compositions for Inhibiting Polyomavirus-Associated Pathology’’ [HHS Ref. No. E–168–2011–0–US–07]; United States Patent Application No. 15/694,567 filed September 1, 2017 and entitled, ‘‘Methods and Compositions for Inhibiting Polyomavirus-Associated Pathology’’ [HHS Ref. No. E–168–2011– 0–US–08]; United States Provisional Patent Application No. 61/919,043 filed December 20, 2013 and entitled, E:\FR\FM\07FEN1.SGM 07FEN1

Agencies

[Federal Register Volume 84, Number 26 (Thursday, February 7, 2019)]
[Notices]
[Page 2555]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-01400]



[[Page 2555]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Cardiovascular and Respiratory Sciences 
Integrated Review Group; Respiratory Integrative Biology and 
Translational Research Study Section.
    Date: February 20-21, 2019.
    Time: 7:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Baltimore Marriott Waterfront, 700 Aliceanna Street, 
Baltimore, MD 21202.
    Contact Person: Bradley Nuss, Ph.D., Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 4142, MSC 7814, Bethesda, MD 20892, 301-451-
8754, nussb@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: February 1, 2019.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-01400 Filed 2-6-19; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.